NCT02177838 · REGISTRY CONDITION SEARCH

Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: NA
Status at capture: TERMINATED
Registry last update: 2021-04-21

This pilot clinical trial studies cetuximab and radiation therapy in treating patients with stage III-IV head and neck cancer. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting certain cells. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cetuximab or cisplatin together with radiation therapy may kill more tumor cells.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Locoregional Control in Cetuximab Responders

→

outcome · POSTED

Percent of Patients Who Progress During Neoadjuvant Cetuximab by CT RECIST 1.1 Criteria

→

outcome · POSTED

Locoregional Control for Non-responders to Neoadjuvant Cetuximab

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically proven squamous cell carcinoma of the oropharynx, hypopharynx or larynx * Stage III/IVa/b squamous cell carcinoma (SCC) by American Joint Committee on Cancer (AJCC) 7 criteria (advanced, but not metastatic) * Patients must give informed consent * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Platelets \>= 100,000/uL * Absolute neutrophil count (ANC) \>= 1,500/uL * Hemoglobin \> 8 g/dl (use of transfusion to achieve this is acceptable) * Total bilirubin \< 2 X institutional upper limit of normal (ULN) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 X institutional ULN * Serum creatinine \< 2 x institutional ULN or creatinine clearance \> 50 ml/min as determined by 24 hour collection or estimated by Cockcroft-Gault formula * Estimated life expectancy of at least 12 weeks * Negative pregnancy test Exclusion Criteria: * Patients may not have received previous therapy for their head and neck SCC, including chemotherapy, radiation therapy, or surgery beyond biopsy * Second primary malignancy; exceptions are 1) patient had a second primary malignancy but has been treated and disease free for at least 3 years, 2) in situ carcinoma (e.g. in situ carcinoma of the cervix), 3) non-melanomatous carcinoma of the skin * Patients with metastatic disease beyond the neck and supraclavicular region will be excluded * Serious concomitant systemic disorders (including active infections) that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator; this includes scleroderma * History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or cisplatinum or other agents used in the study * Women who are pregnant; women of childbearing age must agree to undergo a pregnancy test prior to therapy and to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 6 months after; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Patients with human immunodeficiency virus (HIV) infection are not automatically excluded, but must meet the following criteria: cluster of differentiation (CD)4 count is \> 499/cu mm and their viral load is \< 50 copies/ml; use of highly active anti-retroviral therapy (HAART) is allowed * Patients who have had either myocardial infarction, coronary artery bypass graft, coronary artery stenting, hospital admission for heart related issues such as congestive heart failure or arrhythmia within the last 3 months, will not be allowed on protocol * Grade 3-4 electrolyte abnormalities (Common Terminology Criteria for Adverse Events \[CTCAE\], version \[v\]. 4): * Serum calcium (ionized or adjusted for albumin) \< 7 mg/dl (1.75 mmol/L) or \> 12.5 mg/dl (\> 3.1 mmol/L) despite intervention to normalize levels * Magnesium \< 0.9 mg/dl (\< 0.4 mmol/L) or \> 3 mg/dl (\> 1.23 mmol/L) despite intervention to normalize levels * Potassium \< 3.5 mmol/L or \> 6 mmol/L despite intervention to normalize levels * Sodium \< 130 mmol/L or \> 155 mmol/L despite intervention to normalize levels
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive cetuximab IV over 60-120 minutes for 3 weeks. Patients then undergo EBRT over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy.
intervention Names
Biological: cetuximab
Drug: cisplatin
Radiation: external beam radiation therapy
Other: laboratory biomarker analysis
label
Treatment (cetuximab, cisplatin, EBRT)
type
EXPERIMENTAL

interventions

arm Group Labels
Treatment (cetuximab, cisplatin, EBRT)
description
Given IV
name
cetuximab
other Names
C225
C225 monoclonal antibody
IMC-C225
MOAB C225
monoclonal antibody C225
type
BIOLOGICAL
arm Group Labels
Treatment (cetuximab, cisplatin, EBRT)
description
Given IV
name
cisplatin
other Names
CACP
CDDP
CPDD
DDP
type
DRUG
arm Group Labels
Treatment (cetuximab, cisplatin, EBRT)
description
Undergo EBRT
name
external beam radiation therapy
other Names
EBRT
type
RADIATION
arm Group Labels
Treatment (cetuximab, cisplatin, EBRT)
description
Correlative studies
name
laboratory biomarker analysis
type
OTHER

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 8
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Target number of patients for the study was 27. At the termination of the study, 8 patients were accrued and finished treatment but 1 patient dropped out before follow up, leaving an evaluable number of 7. As the enrollment in the study did not reach the target number of patients, we were not able to produce statistically reliable results to detect the expected difference. Therefore, we have decided to provide summary statistics of primary and secondary outcomes. Among 3 cetuximab responders, two did not have progression within 2 year follow-up time and one had a locoregional recurrence and expired.
measure
Locoregional Control in Cetuximab Responders
time Frame
2 years

secondary Outcomes

description
Among 7 patients, no one progressed during neoadjuvant cetuximab per RECIST 1.1 CT criteria (0%).
measure
Percent of Patients Who Progress During Neoadjuvant Cetuximab by CT RECIST 1.1 Criteria
time Frame
Day 14-21 after the first dose of cetuximab
description
Among 4 cetuximab non-responders, none had locoregional failure at 2 years. Two patients had known HPV status; one patient was HPV+ and another patient HPV-. HPV status for the other two was unknown. HPV positive patient had no sign of progression within 2 years of follow-up. HPV negative patient had no sign of progression for 210 days until the last follow-up. One HPV unknown patient did not show progression within 2 years of follow-up, and the other HPV unknown patient had no progression for 115 days until the last follow-up.
measure
Locoregional Control for Non-responders to Neoadjuvant Cetuximab
time Frame
2 years

Full study description

brief Summary: This pilot clinical trial studies cetuximab and radiation therapy in treating patients with stage III-IV head and neck cancer. Monoclonal antibodies, such as cetuximab, may block tumor growth in different ways by targeting certain cells. Radiation therapy uses high energy x rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cetuximab or cisplatin together with radiation therapy may kill more tumor cells.
detailed Description: PRIMARY OBJECTIVES: I. 2 year (yr) locoregional control in cetuximab responders. SECONDARY OBJECTIVES: I. Assess secondary clinical endpoints such as the percent of patients receiving neoadjuvant cetuximab who progress by computed tomography (CT) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria during the neoadjuvant cetuximab, the 2 yr locoregional control for non-responders to neoadjuvant cetuximab, and the complete response rate to positron emission tomography (PET)/computed tomography (CT) scan 3 months after the completion of radiation therapy for both responders and for non-responders to neoadjuvant cetuximab. II. Analyze the relationship of known deoxyribonucleic acid (DNA) mutations in tumor per the FoundationOne genomic profile, and correlate to clinical endpoints such as locoregional control. II. Analyze any changes in protein production at the tumor in response to 3 weeks of cetuximab. III. Analyze any changes in protein production at the skin in response to 3 weeks of cetuximab. IV. To investigate whether the tumor imaging characteristics including anatomical and molecular parameters evaluated by PET/CT, either alone or combined with other biomarkers can attribute to the better prediction for the clinical outcomes, as the response to neoadjuvant cetuximab; and the final clinical endpoint, the 2-year local regional controls. OUTLINE: Patients receive cetuximab intravenously (IV) over 60-120 minutes for 3 weeks. Patients then undergo external beam radiation therapy (EBRT) over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy. After completion of study treatment, patients are followed up every 3 months for 2 years.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-493b4ff6a67b062e2bcf
requested nct id
NCT02177838
primary nct id
NCT02177838
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
payload sha256
c3882fd801b692c4c65f53daa3489955242178567f84e1d29f6b5ce85d44b87b
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-493b4ff6a67b062e2bcf
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT02177838
occurrences
context exact
NCT02177838
end
11
exact text
NCT02177838
start
0
offset unit
unicode_code_points
query cond
Hypopharyngeal Cancer
query disease state id
ds-hypopharyngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
source json pointer
/studies/50/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
5fe77a02840c7a168c8ce3f498a5d15dc28a934a4311091745d754648cd21366
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-d697464dc8b431720c62
requested nct id
NCT02177838
primary nct id
NCT02177838
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
payload sha256
09528b07d3dd08d782e5f1e5e78f65d3593746659c36c2247c269bb70ad31322
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-d697464dc8b431720c62
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT02177838
occurrences
context exact
NCT02177838
end
11
exact text
NCT02177838
start
0
offset unit
unicode_code_points
query cond
Laryngeal Cancer
query disease state id
ds-laryngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
source json pointer
/studies/62/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
5fe77a02840c7a168c8ce3f498a5d15dc28a934a4311091745d754648cd21366
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice